asunaprevir

an NS3 protease inhibitor against hepatitis C virus

Also Known As:

BMS 650032; BMS-650032; cyclopropanecarboxamide, N-((1,1-dimethylethoxy)carbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, (1R,2S)-

Networked: 216 relevant articles (23 outcomes, 47 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - asunaprevir: 216
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - asunaprevir: 216
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - asunaprevir: 216

Experts

1.	McPhee, Fiona: 26 articles (09/2018 - 03/2012)
2.	Chayama, Kazuaki: 25 articles (01/2020 - 03/2012)
3.	Imamura, Michio: 16 articles (01/2020 - 01/2015)
4.	Kumada, Hiromitsu: 16 articles (01/2020 - 03/2012)
5.	Kawakami, Yoshiiku: 16 articles (12/2018 - 04/2013)
6.	Aikata, Hiroshi: 13 articles (01/2020 - 01/2015)
7.	Tsuge, Masataka: 13 articles (01/2020 - 06/2016)
8.	Ishikawa, Hiroki: 12 articles (01/2019 - 03/2012)
9.	Ochi, Hidenori: 12 articles (12/2018 - 01/2015)
10.	Eley, Timothy: 12 articles (06/2018 - 04/2012)

Related Diseases

1.	Infections 01/01/2017 - "Thus, this study investigates the effect of asunaprevir on innate immunity and its influence on HCV and DENV infection. " 04/01/2012 - "In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. " 04/01/2012 - "In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. " 06/01/2018 - "Asunaprevir (ASV) is a potent, pangenotypic, twice-daily hepatitis C virus (HCV) NS3 inhibitor indicated for the treatment of chronic HCV infection. " 06/01/2018 - "Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection."
2.	Chronic Hepatitis C 01/01/2017 - "Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1." 12/01/2014 - "Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C." 10/01/2013 - "Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C." 04/01/2012 - "Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C." 07/15/2018 - "Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life."
3.	Hepatitis C 01/01/2017 - "Asunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus." 10/01/2015 - "Asunaprevir for hepatitis C: a safety evaluation." 09/01/2018 - "The study cohort comprised 14 transplant recipients with recurrent hepatitis C who were receiving asunaprevir and daclatasvir. " 12/01/2017 - "To assess the impact on the 2015 national health budget of incorporating Daclatasvir/Asunaprevir (DCV / ASV) for the treatment of Hepatitis C genotype 1b (HC1b) in Chile. " 09/08/2017 - "To investigate daclatasvir (DCV) and asunaprevir (ASV) efficacy in hepatitis C (HCV) patients, with respect to resistance-associated substitutions (RASs). "
4.	Fibrosis (Cirrhosis) 01/01/2019 - "Cirrhosis, baseline, and time-varying ALT were significant covariates on asunaprevir apparent oral clearance. " 10/28/2019 - "This study investigated the durability of a sustained virologic response (SVR) and the improvement of fibrosis after daclatasvir and asunaprevir (DCV/ASV) treatment in genotype 1b (GT1b) hepatitis C virus (HCV)-infected patients. " 01/01/2016 - "We compared outcomes by cirrhosis status across studies of the all-oral combination of daclatasvir (DCV) plus asunaprevir (ASV). " 10/28/2019 - "Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study." 03/01/2017 - "Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis."
5.	Liver Cirrhosis (Hepatic Cirrhosis) 07/01/2016 - "In this study, we analyzed the long-term follow up of liver function parameters and liver fibrosis markers in genotype 1b hepatitis C virus (HCV)-infected patients treated with daclatasvir and asunaprevir. " 04/01/2018 - "A 67-year-old woman with HCV genotype 1b and liver cirrhosis received oral daclatasvir and asunaprevir. " 07/01/2016 - "Successful viral eradication by IFN-free daclatasvir and asunaprevir therapy could lead to improved liver function parameters and reduced liver fibrosis markers and AFP levels. " 01/01/2018 - "High serum concentrations of serum asunaprevir, which were associated with the extent of liver fibrosis, appear to provoke the occurrence of liver injury in patients with genotype-1b HCV receiving combined daclatasvir plus asunaprevir therapy." 08/01/2016 - "Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report."

Related Drugs and Biologics

1.	daclatasvir
2.	Ribavirin (Virazole)
3.	Interferons
4.	Sofosbuvir
5.	Antiviral Agents (Antivirals)
6.	Simeprevir
7.	8- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamide
8.	Protease Inhibitors (Protease Inhibitor)
9.	paritaprevir
10.	grazoprevir

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Liver Transplantation
4.	Oral Administration
5.	Drug Tapering